IPO Previews For The Week

With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.

With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.

  • Atmus Filtration Technologies Inc (NYSE:ATMU) will be trading publicly starting on May 26, 2023. The company’s price band is set between $18.00 and $21.00 with an insider lock-up period of 180 days. Atmus Filtration Technologies Inc will be offering 14,124,000 shares at a per-share value of $19.50.
  • FITELL CORPORATION (NASDAQ:FTEL) becomes publicly listed starting on May 26, 2023. The company has a price range set between $4.00 and $6.00 with a 180-day lockup period. FITELL CORPORATION will be offering 3,000,000 shares at a per-share value of $5.00.
  • Azitra Inc (NASDAQ:AZTR) becomes publicly listed starting on May 25, 2023. The company has a price range set between $4.50 and $5.50 with a 180-day lockup period. Azitra Inc will be offering 2,400,000 shares at a per-share value of $5.00.

Evaluating IPOs

An initial public offering, or IPO, is the transitional process of a private company deciding to go public and offer shares to investors on an exchange. Typically, IPOs offer companies the ability to build capital. Before a company becomes publicly listed, it must meet SEC requirements and work with investment banks through audits to determine pricing, offering date, and other important data points before the offering.

Companies and investment banks will work to establish a price range that the stock is expected to sell between. This is known as an offering range. Once a company goes public, its stock comes with an opening price. The insider lock-up period is usually a set number of days after an IPO where company insiders, or employees with a 10% or higher stake in their company, cannot sell shares.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Rona Therapeutics Announced Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform

Rona Therapeutics, Inc ("Rona"), a fully integrated platform company dedicated to the discovery, development and manufacturing of RNA therapeutics, today announced that it has obtained worldwide exclusive rights to Sanofi's siRNA platform of chemical modification and delivery moiety as well as rights to four pre-clinical candidates for undisclosed targets.

SNY